Emerging Growth Equities, Ltd. Initiates Coverage of Zoll Medical Corp. (Nasdaq:
ZOLL) With a STRONG BUY Rating
KING OF PRUSSIA, Pa., March 2 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of Zoll Medical Corp. with a STRONG BUY rating and a
12-month price target of $50.00. Zoll Medical is a leading manufacturer and
distributor of defibrillation-based cardiac resuscitation and related pacing and
patient monitoring devices to hospitals, emergency medical personnel, and police
and fire departments.
Emerging Growth Equities, Ltd., is a specialty brokerage and investment banking
firm providing high quality distribution, research and trade execution for
institutional and retail clients. Emerging Growth Equities, Ltd., specializes
in fulfilling the capital requirements of well-managed emerging growth
companies. Emerging Growth Equities, Ltd. maintains a market in ZOLL with the
market maker ID EGRO.
For a full text of the report please call 888-293-1800.
This publication is neither an offer to sell nor a solicitation to buy any
securities mentioned herein. The information contained herein is based on data
obtained from recognized sources that are believed to be reliable. Emerging
Growth Equities, Ltd. has not independently verified the facts, assumptions and
estimates contained in this report. Accordingly, no representation or warranty,
expressed or implied, is made as to, and no reliance should be placed on, the
fairness, accuracy, completeness or correctness of the information and opinions
contained in this report. The information contained in this report is not and
does not purport to be a complete analysis of every material fact respecting any
company, industry, or security.
Most of the companies Emerging Growth Equities, Ltd. follows are emerging and
mid-sized growth companies whose securities typically involve a higher degree of
risk and more volatility than the securities of more established companies. For
these and other reasons, the investments discussed or recommended in this report
may be unsuitable for investors depending on their specific investment
objectives and financial position. Transactions in securities mentioned herein
may be effected only in those states where such securities are qualified for
sale.
Any statements nonfactual in nature herein constitute only current opinions or
estimates, represent only the current judgment of the author(s), and are subject
to change without notice. This report contains forward- looking statements,
which involve risks and uncertainties. Actual results may differ significantly
from the results described in the forward-looking statements. Emerging Growth
Equities, Ltd. (or one of its affiliates) or their partners, officers,
directors, analysts, employees or customers may have an interest in the
securities mentioned herein and may make purchases or sales as principal or
agent of these securities, or their derivatives, while this report is in
circulation. A partner, employee, analyst, officer, or director of Emerging
Growth Equities, Ltd. (or one of its affiliates) may serve as a director or
consultant for any company mentioned herein. Emerging Growth Equities, Ltd. (or
one of its affiliates) may from time to time perform investment banking services
for, or solicit investment banking business or other business from, any company
mentioned herein. Additional information on the securities discussed herein is
available on request.
Emerging Growth Equities, Ltd. is a member of the National Association of
Securities Dealers, CRD number 47040. DATASOURCE: Emerging Growth Equities, Ltd.
CONTACT: Raymond A. Myers, CFA, Healthcare Analyst, Emerging Growth Equities, Ltd., +1-610-783-4783 or +1-888-293-1800
|